Loading...
Medreich Limited — Bisacodyl Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #5 for Bisacodyl · $399.9K export value · DGFT Verified
Medreich Limited is the #5 Indian exporter of Bisacodyl with $399.9K in export value and 21 verified shipments. Medreich Limited holds a 4.6% market share in Bisacodyl exports across 5 countries. The company exports 42 pharmaceutical products worth $224.8M across 15 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| CZECH REPUBLIC | $154.0K | 7 | 38.5% |
| FRANCE | $148.5K | 5 | 37.1% |
| NEW ZEALAND | $67.7K | 6 | 16.9% |
| AUSTRALIA | $25.2K | 2 | 6.3% |
| NIGERIA | $4.4K | 1 | 1.1% |
Medreich Limited exports Bisacodyl to 5 countries. The largest destination is CZECH REPUBLIC accounting for 38.5% of Medreich Limited's Bisacodyl shipments, followed by FRANCE (37.1%) and NEW ZEALAND (16.9%). These destinations reflect Medreich Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SUBSTIPHARM | FRANCE | $148.5K | 5 |
| MEDIS INTERNATIONAL AS | CZECH REPUBLIC | $70.7K | 3 |
| MEDIS INTERNATIONAL A.S. | CZECH REPUBLIC | $62.3K | 3 |
| VIATRIS NEW ZEALAND | NEW ZEALAND | $55.4K | 5 |
| MEDREICH AUSTRALIA PTY LTD | AUSTRALIA | $25.2K | 2 |
| MEDIS INTERNATIONAL A S | CZECH REPUBLIC | $21.0K | 1 |
India exported $6.4M worth of Bisacodyl through 1,294 shipments from 240 suppliers to 108 countries, serving 415 buyers globally. Medreich Limited contributes $399.9K to this total, accounting for 4.6% of India's Bisacodyl exports. Medreich Limited ships Bisacodyl to 5 countries through 8 buyers.
Medreich Limited's average Bisacodyl shipment value is $19.0K per consignment, based on 21 shipments totaling $399.9K. The largest destination is CZECH REPUBLIC (38.5% of Medreich Limited's Bisacodyl exports).
Medreich Limited ranks #5 among 240 Indian Bisacodyl exporters with a 4.6% market share. The top 3 exporters are DR.REDDY'S LABORATORIES LTD ($2.0M), IND SWIFT LIMITED ($760.7K), BLISS GVS PHARMA LIMITED ($712.9K). Medreich Limited processed 21 shipments to 5 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BISACODYL GASTRO RESISTANT TABLETS 5MG,3 | $62.3K | 3 |
| BISACODYL GASTRO RESISTANT TABLETS 5MG,30000S234.972 | $35.2K | 1 |
| BISACODYL 5MG TABLETS( Bisacodyl ViatrisConseil 5MG) (3X10'S) (46860 packs) | $30.9K | 1 |
| BISACODYL 5MG TABLETS( Bisacodyl ViatrisConseil 5MG) (3X10'S) (45636 packs) | $30.1K | 1 |
| BISACODYL 5MG TABLETS (BISACODYL VIATRISCONSEIL 5MG) 3X10'S(QTY 45900) | $30.0K | 1 |
| BISACODYL 5MG TABLETS (BISACODYL VIATRISCONSEIL 5MG) 3X10'S(QTY 45564) | $29.8K | 1 |
| BISACODYL GASTRO RESISTANT TABLETS 5MG 30000SQTY-189.140 | $28.4K | 1 |
| BISACODYL 5MG TABLETS( Bisacodyl ViatrisConseil 5MG) 3X10S(46380 PACKS) | $27.7K | 1 |
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | BLISS GVS PHARMA LIMITED | $712.9K | 26 | 3 | $27.4K |
| 4 | DR REDDYS LABORATORIES LIMITED | $458.7K | 12 | 1 | $38.2K |
| 5 | MEDREICH LIMITED ★ | $399.9K | 21 | 5 | $19.0K |
| 6 | DR.REDDY'S LABORATORIES LIMITED | $291.9K | 19 | 1 | $15.4K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 168 | 13.0% |
| NHAVA SHEVA SEA (INNSA1) | 159 | 12.3% |
| SAHAR AIR | 152 | 11.7% |
| JNPT/ NHAVA SHEVA SEA | 74 | 5.7% |
| HYDERABAD ICD | 60 | 4.6% |
| JNPT | 58 | 4.5% |
| Bombay Air | 42 | 3.2% |
| AHEMDABAD ICD | 32 | 2.5% |
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Medreich Limited. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased shipping costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structures of exporters relying on these routes. (sgeexport.com)
Conversely, the US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. However, the imposition of tariffs on pharmaceutical imports by the US poses a risk to Indian companies, as higher tariffs could render low-margin generic drugs unprofitable, leading to market exits and exacerbating drug shortages in the US. (cfo.economictimes.indiatimes.com)
The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a favorable development for Medreich. The FTA eliminates tariffs on Indian pharmaceutical products entering the EU, providing immediate cost relief and enhancing market access. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, creating new opportunities for companies like Medreich to expand their presence in the EU market. (en.wikipedia.org)
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The US Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practices (EU GMP) set stringent quality requirements that companies must adhere to for market access. Recent regulatory frameworks have increased compliance costs by an average of 18.7%, leading to a 15.2% reduction in export volumes to the US in the first quarter of 2025. (transdatanexus.com)
For Medreich Limited, maintaining compliance with these evolving standards is crucial to sustaining and expanding its export markets. Investments in quality assurance, regular audits, and staying abreast of regulatory changes are essential strategies to navigate this complex landscape.
Medreich Limited exports 42 products worth $224.8M. Beyond Bisacodyl, top products include Amoxicillin, Potassium, Flucloxacillin, Rosuvastatin, Atorvastatin. View the complete Medreich Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Bisacodyl — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Medreich Limited's Bisacodyl exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Medreich Limited
Full Company Profile →
42 products · $224.8M total trade · 15 categories
| MYLAN NEW ZEALAND LTD |
| NEW ZEALAND |
| $12.4K |
| 1 |
| AGUAWKA VENTURES LTD | NIGERIA | $4.4K | 1 |
Medreich Limited supplies Bisacodyl to 8 buyers globally. The largest buyer is SUBSTIPHARM (FRANCE), followed by MEDIS INTERNATIONAL AS (CZECH REPUBLIC) and MEDIS INTERNATIONAL A.S. (CZECH REPUBLIC). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| BISACODYL TABLETS 5MG (BISACODYL VIATRIS | $25.8K | 2 |
| BISACODYL GASTRO RESISTANT TABLETS 5MG 30000S 141 038 QTY | $21.0K | 1 |
Medreich Limited exports 18 distinct Bisacodyl formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BISACODYL GASTRO RESISTANT TABLETS 5MG,3 with 3 shipments worth $62.3K.
| 7 |
| DR REDDY S LABORATORIES LIMITED |
| $282.8K |
| 10 |
| 1 |
| $28.3K |
Medreich Limited ranks #5 among 240 Indian Bisacodyl exporters. Average shipment value of $19.0K compared to the market average of $26.5K. The closest competitors by value are BLISS GVS PHARMA LIMITED and DR REDDYS LABORATORIES LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 108+ countries, 415+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Medreich Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Bisacodyl. For current shipment-level data, contact TransData Nexus.